leisure time -WSS

leisure time

author：Wikipedia 2025-09-27 17:02:02 - browse：62

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both sickle cell disease and beta thalassemia, making it the world’s first therapy built on the revolutionary gene-editing technology and ushering in a new era of genetic medicine.

The authorization of the therapy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is itself not a surprise. Clinical trials have shown the one-time treatment enabled many sickle cell patients to live free of debilitating pain crises and relieved thalassemia patients of needing regular blood transfusions, raising hopes that they have been effectively cured. But it also stands as a major achievement, coming just over a decade after the first and seminal lab experiments that showed CRISPR’s potential as a gene-editing tool were published.

In granting conditional approval to the therapy, which will have the brand name Casgevy and is also known as exa-cel, the U.K.’s Medicines and Healthcare products Regulatory Agency jumped ahead of its counterparts in the U.S. and Europe, which are also reviewing the medicine, in greenlighting the globe’s first CRISPR treatment. The MHRA’s authorization is for patients who are at least 12 years old.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： FDA clears AI tool for detecting skin cancer

knowledge

focus

hotspot

WSS

Menendez indictment could see pharma lose a key ally

How digital therapeutics firms are pivoting after Pear's bankruptcy

WHO recommends dropping component of many flu vaccines

Health tech startups drop sharply from 2021 highs

FDA seeks to regulate lab

Kaiser Permanente unions announce official strike date

explore

leisure time

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Biotech venture capitalists face new demands from investors

Psychedelics group wrestles with new pharma identity

FDA seeks to regulate lab

DIEP, the 'gold standard' of breast reconstruction, is under threat

New brain studies show LSD's effects on the brain in full color

Drug repurposing or repositioning? The language matters

Dewpoint Therapeutics lays off staff after losing partnerships

How one medical school became remarkably diverse

Menendez indictment could see pharma lose a key ally

Wikipedia

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

The surgeon had a dilemma only a Nazi medical text could resolve

How digital therapeutics firms are pivoting after Pear's bankruptcy

Inequities make cancer less preventable for women: report

The surgeon had a dilemma only a Nazi medical text could resolve

Why do women spend more than men on medical expenses?

knowledge

focus

hotspot

focus